Related references
Note: Only part of the references are listed.Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis
Hiroaki Yokomori et al.
BMJ OPEN GASTROENTEROLOGY (2020)
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Maurizio Parola et al.
MOLECULAR ASPECTS OF MEDICINE (2019)
The GLP-1 Receptor Agonist Liraglutide Improves Hepatic Inflammation and Fibrosis in a Mouse Model of NASH
Sophie A. Montandon et al.
DIABETES (2019)
Linagliptin inhibits high glucose-induced transdifferentiation of hypertrophic scar-derived fibroblasts to myofibroblasts via IGF/Akt/mTOR signalling pathway
Yan Li et al.
EXPERIMENTAL DERMATOLOGY (2019)
The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis
Hannah V. Woodcock et al.
NATURE COMMUNICATIONS (2019)
MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH
Michelle Beaton et al.
DIABETES (2018)
The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
Jessica Lawrence et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Liver fibrosis: Direct antifibrotic agents and targeted therapies
Detlef Schuppan et al.
MATRIX BIOLOGY (2018)
Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis
Isabel Fabregat et al.
FRONTIERS IN ONCOLOGY (2018)
Comparison of serological assessments in the diagnosis of liver fibrosis in bile duct ligation mice
Chengxia Xie et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2017)
Protective effects of silymarin against bisphenol A-induced hepatotoxicity in mouse liver
Mihaela Zaulet et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)
Experimental models of liver fibrosis
Sara Crespo Yanguas et al.
ARCHIVES OF TOXICOLOGY (2016)
GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway
Qin He et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Effect of Linagliptin on Structural Changes in the Kidney in Experimental Type 2 Diabetes Mellitus
Yu. S. Gavrilova et al.
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2016)
Linagliptin Ameliorates MethylglyoxalInduced Peritoneal Fibrosis in Mice
Takuo Nagai et al.
PLOS ONE (2016)
mTOR Overactivation in Mesenchymal cells Aggravates CCl4 - Induced liver Fibrosis
Lanlan Shan et al.
SCIENTIFIC REPORTS (2016)
Antifibrotics in chronic liver disease: tractable targets and translational challenges
Prakash Ramachandran et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)
Strategies to prevent and reverse liver fibrosis in humans and laboratory animals
Rong-Jane Chen et al.
ARCHIVES OF TOXICOLOGY (2015)
Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin
Michael Zeisberg et al.
KIDNEY INTERNATIONAL (2015)
The carbon tetrachloride model in mice
D. Scholten et al.
LABORATORY ANIMALS (2015)
mTOR signalling is an essential pathway for TGF-β1 induced collagen synthesis
Hannah Woodcock et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
Keizo Kanasaki et al.
DIABETES (2014)
Probable linagliptin-induced liver toxicity: A case report
E. Kutoh
DIABETES & METABOLISM (2014)
Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats
Kosuke Kaji et al.
JOURNAL OF GASTROENTEROLOGY (2014)
IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples
Frency Varghese et al.
PLOS ONE (2014)
Silymarin Inhibits Cell Cycle Progression and mTOR Activity in Activated Human T Cells: Therapeutic Implications for Autoimmune Diseases
Marjan Gharagozloo et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2013)
Evolving therapies for liver fibrosis
Detlef Schuppan et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Review of Linagliptin for the Treatment of Type 2 Diabetes Mellitus
Joshua J. Neumiller et al.
CLINICAL THERAPEUTICS (2012)
IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C. Part 9: Reference procedure for the measurement of catalytic concentration of alkaline phosphatase
Gerhard Schumann et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
Therapy in the Early Stage: Incretins
Simona Cernea et al.
DIABETES CARE (2011)
Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis
Eva Tomas et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation
G Carpino et al.
DIGESTIVE AND LIVER DISEASE (2005)
IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase
G Schumann et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2002)
IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase
G Schumann et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2002)
Share Paper
